• Aucun résultat trouvé

[PDF] Top 20 Targeted Therapies in Adult B-Cell Malignancies

Has 10000 "Targeted Therapies in Adult B-Cell Malignancies" found on our website. Below are the top 20 most common "Targeted Therapies in Adult B-Cell Malignancies".

Targeted Therapies in Adult B-Cell Malignancies

Targeted Therapies in Adult B-Cell Malignancies

... novel targeted drugs such as ibrutinib and idelalisib [ 76 ...Process. In the early twentieth century, War- burg first discovered that cancer cells preferentially consume glucose and metabolize it to ... Voir le document complet

18

Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype

Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype

... Abstract Adult T-cell leukemia/lymphoma (ATL) carries a poor prognosis even in indolent ...performed targeted deep sequencing combined with mapping of HTLV-1 proviral integration sites of 61 ... Voir le document complet

13

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

... altered in more than 80% of all PDAC patients. In PDAC, preneoplastic lesions (pancreatic intraepithelial neoplasia (PanIN), mucinous cystic neoplasm (MCM) and intra-ductal papillary mucinous neoplasm ... Voir le document complet

26

RNA Splicing, Cell Signaling and Response to Therapies

RNA Splicing, Cell Signaling and Response to Therapies

... biomarkers. In addition, the functional consequences of hot spot mutations affecting various components of the spliceosome machinery in cancers have been ...pre-mRNA in response to hot spot mutation ... Voir le document complet

24

Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies

Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies

... In addition to fibronectin, another ECM structural protein whose production by melanoma cells is affected by inhibitors of the MAPK pathway is type I collagen [ 12 , 92 ...increased in vitro and in ... Voir le document complet

21

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers

... Lymphoma in 2015(1), despite the availability of modern immunochemotherapy regimens and the introduction of novel agents such as ibrutinib and ...improvements in the therapeutic armamentarium for ... Voir le document complet

24

Chimeric antigen receptor T-cells: a new therapeutic option for relapsed/refractory B-cell malignancies and beyond

Chimeric antigen receptor T-cells: a new therapeutic option for relapsed/refractory B-cell malignancies and beyond

... diseases in which CAR T-cells were ...CLL in 2011, results have been reported of CD19-targeted CAR T-cell therapy in a total of 134 CLL ...being in relapse after a large number ... Voir le document complet

10

View of Cardiovascular Toxicity Due to Chemotherapy, Targeted Therapies, and Immunosuppressive Drugs: a Narrative Review

View of Cardiovascular Toxicity Due to Chemotherapy, Targeted Therapies, and Immunosuppressive Drugs: a Narrative Review

... admissions in these patients, various cardiovas- cular toxicities may occur during multiple lines of chemo- therapy and targeted therapies, with progressively higher cumulative ...fied in 1950 ... Voir le document complet

14

Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology.

Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology.

... of adult articular cartilage to regenerate is ...or cell-based therapies using chondro- cytes) may lead to fi brocartilage and not restore hyaline articular cartilage in the long ...implanted ... Voir le document complet

7

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

... were adult patients (≥18 years); (ii) had de novo or sec- ondary AML or MDS; (iii) received a reduced-intensity or reduced- toxicity conditioning regimen including fludarabine, ... Voir le document complet

8

Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis

Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis

... inflammation- targeted therapy with anti-interleukin (IL)-1β neutralizing antibodies [ 1 ] or colchicine [ 2 , 3 ] for the prevention of recurrent events in patients recovering from an acute coronary syn- ... Voir le document complet

18

ImmunoPET to help stratify patients for targeted therapies and to improve drug development

ImmunoPET to help stratify patients for targeted therapies and to improve drug development

... changes in properties and heterogeneity during ...increase in the use of targeted therapies, including monoclonal antibodies (mAbs), in cancer ...mAbs in advanced clinical ... Voir le document complet

4

RNA Splicing, Cell Signaling and Response to Therapies

RNA Splicing, Cell Signaling and Response to Therapies

... biomarkers. In addition, the functional consequences of hot spot mutations affecting various components of the spliceosome machinery in cancers have been ...pre-mRNA in response to hot spot mutation ... Voir le document complet

23

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.

... epitopes. In the last few decades, BsAbs have been developed within the context of cancer therapies and in particular for the treatment of hematologic B-cell ...Advances in ... Voir le document complet

20

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies : An Update of the Pivotal Clinical Trial Center

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies : An Update of the Pivotal Clinical Trial Center

... investigated in CAR-T-cell studies, but yielded varying results ...pursued in an attempt to improve response durability ...antigen in MM, because myeloma cells are mostly CD19-negative by flow ... Voir le document complet

15

Monitoring NK cell activity in patients with hematological malignancies

Monitoring NK cell activity in patients with hematological malignancies

... affected in the course of tumor progression, how the activity of circulating NK cells correlate with relapse or complications, how such an activity might be improved, and how various anticancer agents currently ... Voir le document complet

7

Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders

Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders

... Sustained, targeted, high-level transgene expression in primary B lymphocytes may be useful for gene ther- apy in B cell ...candidate B-lineage predominant ... Voir le document complet

11

B cell differentiation is defective in Multiple Sclerosis patients

B cell differentiation is defective in Multiple Sclerosis patients

... cells in MS patients Figure ...patients in relapse (A) MS patients have a significant higher frequency of T FH cells within their CSF compared to their blood ...1.56% in blood, p ... Voir le document complet

2

Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity

Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity

... noticed in a significant proportion of patients and predominant mode of inheritance is autosomal dominant, with some cases with an X-linked transmission 7 ... Voir le document complet

38

Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a ‘treatabolome’

Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a ‘treatabolome’

... sharing in rare genetic ...terms in RD-CONNECT) results in a higher diagnostic ...variants in the genes highlighted as part of the treatabolome project will be flagged in RD- ... Voir le document complet

19

Show all 10000 documents...